PMEF
VRTX icon

Point72 Middle East FZE’s Vertex Pharmaceuticals VRTX Stock Holding History

Point72 Middle East FZE’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,700
Closed -$2.73M – 1292
2023
Q4 		$2.73M Buy
6,700
+6,400
+2,133% +$2.36M 0.08% 329
2023
Q3 		$104K Sell
300
-400
-57% -$140K ﹤0.01% 1139
2023
Q2 		$246K Sell
700
-100
-13% -$33.7K 0.01% 988
2023
Q1 		$252K Sell
800
-100
-11% -$30K 0.01% 874
2022
Q4 		$260K Buy
+900
New +$274K 0.01% 947

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Point72 Middle East FZE's VRTX Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 32,326 shares — an estimated $11.9M sold.

Point72 Middle East FZE first reported a position in VRTX in Q4 2022 and held it in 3 quarters. The position peaked at $11.2M in Q3 2023. 1,440 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 32,326 Vertex Pharmaceuticals shares in Q4 2023, an estimated $11.9M.
  • Point72 Middle East FZE first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Point72 Middle East FZE's Vertex Pharmaceuticals position peaked at $11.2M in Q3 2023.
  • 1,440 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.